TriSalus Life Sciences, Inc. TLSI

4.34 (0.27) (5.86%) as of 25 Sep
Market cap
$303.6M
P/E
0.0×
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
889.44% 529.28% 233.25% 306.43%

+8 more TTM periods

ROA
(110.34%) (114.58%) (235.03%) (226.01%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(113.57%) (97.89%) (309.01%) (298.03%)
Average Days of Receivables
52.30 42.41 53.01 45.39
Free Cash Flow per Share
(0.40) (0.39) (0.50) (0.51)
Free Cash Flow
(23.24) (20.26) (18.85) (22.08)
Capital Expenditures
(0.44) (0.26) (0.84) (0.85)
Piotroski F-Score
4.00 4.00 3.00 3.00
Other line items
Cash ROIC
(26.54%) (19.52%) (91.79%) (73.92%)
Accounts Receivable Turnover
7.49 8.41 7.75 8.11
Accounts Payable Turnover
2.26 1.90 2.64 2.45
Inventory Turnover
1.60 1.69 1.96 1.76
Average Days of Payables
214.41 230.55 157.32 215.17
Days of Inventory on Hand
239.59 205.82 161.25 186.28
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
32.45% 33.78% 33.14% 36.87%
Selling, General and Administrative Expense of Revenue
121.02% 113.74% 111.11% 124.90%
Share Based Compensation of Revenue
23.75% 22.24% 20.22% 21.47%
Interest Coverage
0.00 0.00 0.00 0.00
Operating CF/Net income
0.40 0.35 0.26 0.29
Depreciation/Fixed assets
0.95 0.87 0.93 0.90
Capex/Depreciation
(0.25) (0.16) (0.50) (0.52)
Revenue per Share
0.77 0.87 1.19 0.93
Operating CF per Share
(0.39) (0.39) (0.48) (0.49)
Capex per Share
(0.01) (0.01) (0.02) (0.02)
Capex to Sales
0.01 0.01 0.02 0.02
Net Profit Margin
(127.00%) (127.14%) (154.35%) (179.71%)

Fold the line items

Columns are period end dates